HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dermatofibrosarcoma protuberans of the vulva: a clinicopathologic and immunohistochemical study of 13 cases.

Abstract
Dermatofibrosarcoma protuberans (DFSP) is a low-grade sarcoma seldom seen in the vulva with only 29 cases reported. We present the clinicopathologic and immunohistochemical features of 13 such cases seen in our institution over a period of 29 years (1978 to 2007). Patient age ranged from 23 to 76 years (mean, 46 y). Twelve patients had a vulvar mass. One patient presented with a pigmented skin lesion. Tumor size ranged from 1.2 to 15 cm (median, 4 cm). Microscopically, all the cases showed typical features of DFSP. In 1 case, myxoid changes were also noted; 3 cases showed fibrosarcomatous transformation. Of interest, in 7 of our 13 cases, a variety of diagnoses, such as cellular dermatofibroma, cellular leiomyoma, neurofibroma, low-grade leiomyosarcoma, fibrosarcoma, low-grade malignant schwannoma, desmoplastic melanoma, cellular neurofibroma, and low-grade malignant peripheral nerve sheet tumor were initially considered. All 11 cases tested for CD34 were positive, whereas 7/9 cases, 8/9 cases, and 9/9 cases were positive for PDGFR-alpha, PDGFR-beta, and c-abl, respectively. All patients were initially treated with excisional biopsy, wide local excision, or radical vulvectomy. Local recurrences occurred in 7 cases. One patient also developed distant metastases. All recurrences were treated surgically; 1 patient also received chemotherapy and radiotherapy and another received imatinib (Gleevec). Follow-up data ranging from 2 to 444 months was available for all patients. Nine patients had no evidence of disease, 2 patients were alive with disease, 1 patient had died of disease, and 1 patient had died of other causes. DFSP affects women of a wide age range and has a propensity to recur locally. The frequent expression of PDGFR-alpha, PDGFR-beta, and c-abl in these cases agrees with the findings of other investigators and supports the use of imatinib (Gleevec) in cases that are recurrent or not amenable to surgery.
AuthorsMarcia Edelweiss, Anais Malpica
JournalThe American journal of surgical pathology (Am J Surg Pathol) Vol. 34 Issue 3 Pg. 393-400 (Mar 2010) ISSN: 1532-0979 [Electronic] United States
PMID20139758 (Publication Type: Journal Article)
Chemical References
  • Biomarkers, Tumor
Topics
  • Adult
  • Aged
  • Biomarkers, Tumor (analysis)
  • Chemotherapy, Adjuvant
  • Dermatofibrosarcoma (chemistry, diagnosis, mortality, secondary, therapy)
  • Diagnosis, Differential
  • Female
  • Gynecologic Surgical Procedures
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Predictive Value of Tests
  • Radiotherapy, Adjuvant
  • Reoperation
  • Skin Neoplasms (chemistry, diagnosis, mortality, pathology, therapy)
  • Time Factors
  • Treatment Outcome
  • Vulvar Neoplasms (chemistry, diagnosis, mortality, pathology, therapy)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: